ARCHIVES

Gleevec Approval Sets Record For FDA Review: 73 Days

This article is from The Cancer Letter archive.

Vol. 24 No. 5 | May 25, 2001

Download PDF Visit The Full Archive

Related Articles

With A Flat Budget, Niederhuber Outlines NCI Priorities In Speech To ASCO Meeting.

June 13, 2008

NCI Intramural Programs: Clinical Trials Support System Need Attention, report Advises DCS

December 19, 1997

FDA Approves DNA Test For Two Types of HPV

March 27, 2009

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

March 28, 2014

Funding Opportunity: PanCAN Offering $4.1 Million in Research Grants

September 12, 2014

Recompetitions Of DCT Contracts Okayed

March 3, 1989